Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Follow-up of Gene Therapy With Lovotibeglogene Autotemcel in Sickle Cell Disease
2024-513901-30-00Phase 3Authorised
- Sponsor
- bluebird bio
- Start
- Jun 2024
- Modality
- Cell Therapies, Gene Therapies
- Countries
- 2
01
Overview
Phase 3, open-label, single-arm trial of lovotibeglogene autotemcel in sickle cell disease (SCD), sponsored by bluebird bio. Primary endpoints: Immune-related adverse events, New or worsening hematologic disorders and 2 more. Planned start Jun 2024; status: authorised.
02
Drugs
lovotibeglogene autotemcel
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on 2024-513901-30-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513901-30-00.